Jonathan P. Caulkins — Publications

America's Opioid Ecosystem: How Leveraging System Interactions Can Help Curb Addiction, Overdose, and Other Harms 2023
The Ecosystem Approach to Opioid Policy 2023
How Much Illegally Manufactured Fentanyl Could the U.S. Be Consuming? 2022
Rapid Changes in Illegally Manufactured Fentanyl Products and Prices in the United States 2022
Cannabis Legalization and Social Equity: Some Opportunities, Puzzles, and Trade-Offs 2021
Heroin Use Cannot Be Measured Adequately with a General Population Survey 2021
The Dawn of a New Synthetic Opioid Era: The Need for Innovative Interventions 2020
Variation in the Degree of Concentration of Prescription Opioid Utilization Using Different Measures 2020
After the Grand Opening: Assessing Cannabis Supply and Demand in Washington State 2019
The Future of Fentanyl and Other Synthetic Opioids 2019
Supervised Consumption Sites: A Nuanced Assessment of the Causal Evidence 2019
The Synthetic Opioid Surge in the United States: Insights from Mortality and Seizure Data 2019
Triangulating Web & General Population Surveys: Do Results Match Legal Cannabis Market Sales? 2019
Understanding America's Surge in Fentanyl and Other Synthetic Opioids 2019
What America's Users Spend on Illegal Drugs, 2006–2016 2019
Acceptability of Heroin-Assisted Treatment and Supervised Drug Consumption Sites to Address the Opioid Crisis in the United States: Key Informant Perspectives 2018
Assessing the Evidence on Supervised Drug Consumption Sites 2018
Big Data on a Big New Market: Insights from Washington State's Legal Cannabis Market 2018
Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States 2018
Variation in Cannabis Potency and Prices in a Newly Legal Market: Evidence from 30 Million Cannabis Sales in Washington State 2017
Considering Marijuana Legalization Carefully: Insights for Other Jurisdictions from Analysis for Vermont 2016
Marijuana Legalization: What Everyone Needs to Know (Second Edition) 2016
Modeling the Structure and Operation of Drug Supply Chains: The Case of Cocaine and Heroin in Italy and Slovenia 2016
Beyond Prevalence: Importance of Estimating Drug Consumption and Expenditures 2015
Cocaine's Fall and Marijuana's Rise: Questions and Insights Based on New Estimates of Consumption and Expenditures in U. S. Drug Markets 2015
Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions 2015
How Much of the Cocaine Market Are We Missing? Insights from Respondent-Driven Sampling in a Mid-Sized American City 2015
The Marijuana Legalization Debate: Insights for Vermont 2015
Options and Issues Regarding Marijuana Legalization 2015
Are Users' Most Recent Drug Purchases Representative? 2014
Criminal Justice Costs of Prohibiting Marijuana in California 2014
Developing Public Health Regulations for Marijuana: Lessons from Alcohol and Tobacco 2014
How Big Is the U.S. Market for Illegal Drugs? 2014
What America's Users Spend on Illegal Drugs: 2000–2010 2014
Before the Grand Opening: Measuring Washington State's Marijuana Market in the Last Year Before Legalized Commercial Sales 2013
Estimating the Size of the EU Cannabis Market 2013
High Tax States: Options for Gleaning Revenue from Legal Cannabis 2013
Multinational overview of cannabis production regimes 2013
Quasi-legal Cannabis in Colorado and Washington: Local and National Implications 2013
Statistics on Cannabis Users Skew Perceptions of Cannabis Use 2013
The Whole Is Just the Sum of Its Parts: Limited Polydrug Use Among the "Big Three" Expensive Drugs in the United States 2013
Design Considerations for Legalizing Cannabis: Lessons Inspired by Analysis of California's Proposition 19 2012
Epidemiological Model for Examining Marijuana Use Over the Life Course 2012
Scheduling of Newly Emerging Drugs: A Critical Review of Decisions Over 40 Years 2012
The U.S. Drug Policy Landscape: Insights and Opportunities for Improving the View 2012
Addiction Research Centres and the Nurturing of Creativity: RAND's Drug Policy Research Center 2011
Basing Drug Scheduling Decisions on Scientific Ranking of Harmfulness: False Promise from False Premises 2011
Bringing Perspective to Illicit Markets: Estimating the Size of the U.S. Marijuana Market 2011
Budgeting for Immigration Enforcement: A Path to Better Performance 2011
Altered State? Assessing How Marijuana Legalization in California Could Influence Marijuana Consumption and Public Budgets 2010
Cost of Marijuana Prohibition on the California Criminal Justice System 2010
Estimated Cost of Production for Legalized Cannabis 2010
How Might Marijuana Legalization in California Affect Drug Trafficking Revenues and Violence in Mexico? 2010
How Might Marijuana Legalization in California Affect Public Budgets and Marijuana Consumption? 2010
Potential for Legal Marijuana Sales in California to Supply Rest of U.S. 2010
RAND Review: Vol. 34, No. 2, Summer 2010 2010
Reducing Drug Trafficking Revenues and Violence in Mexico: Would Legalizing Marijuana in California Help? 2010
Smuggling and Excise Tax Evasion for Legalized Marijuana: Lessons from Other Excise Taxes 2010
What Economics Can Contribute to the Addiction Sciences 2010
Marijuana Markets: Inferences from Reports by the Household Population 2006
Assessing U.S. Drug Problems and Policy: A Synthesis of the Evidence to Date 2005
How Goes the “War on Drugs”? An Assessment of U.S. Drug Problems and Policy 2005
Models Pertaining to How Drug Policy Should Vary Over the Course of a Drug Epidemic 2005
What We Can--And Cannot--Expect from School-Based Drug Prevention 2004
Crash Courses: Hard Lessons from Educational Interventions 2003
Drug Use and Drug Policy Futures: Insights from a Colloquium 2003
International Drug Prices: Evidence from STRIDE 2003
RAND Review: Vol. 27, No. 1, Spring 2003 2003
Intelligent Giving: Insights and Strategies for Higher Education Donors 2002
Law Enforcement's Role in a Harm Reduction Regime 2002
A "Noble Bet" in Early Care and Education: Lessons from One Community's Experience 2002
A "Noble Bet" in Early Care and Education: Lessons from One Community's Experience: Executive Summary 2002
School-Based Drug Prevention: What Kind of Drug Use Does It Prevent? 2002
What Are the True Benefits of School-Based Drug Prevention Programs? 2002
Analyzing the Costs and Benefits of Early Childhood Interventions 2001
Assessing Costs and Benefits of Early Childhood Intervention Programs: Overview and Applications to the Starting Early, Starting Smart Program: Executive Summary 2001
Assessing Costs and Benefits of Early Childhood Intervention Programs: Overview and Applications to the Starting Early, Starting Smart Program 2001
Drug Prices and Emergency Department Mentions for Cocaine and Heroin 2001
The Evolution of Drug Initiation: From Social Networks to Public Markets 2001
Do Drug Prohibition and Enforcement Work? 2000
A Dynamic Model of Drug Initiation: Implications for Treatment and Drug Control 2000
The Global Course of the Information Revolution: Technological Trends: Proceedings of an International Conference 2000
Measurement and Analysis of Drug Problems and Drug Control Efforts 2000
Optimal Control of Drug Epidemics: Prevent and Treat--But Not at the Same Time? 2000
Response to the National Research Council's Assessment of RAND's "Controlling Cocaine" Study 2000
Should the U.S. Direct More Law Enforcement Effort at XTC? 2000
The Benefits and Costs of Drug Use Prevention: Clarifying a Cloudy Issue 1999
An Ounce of Prevention, a Pound of Uncertainty: The Cost-Effectiveness of School-Based Drug Prevention Programs 1999
Are mandatory minimum drug sentences cost-effective? 1998
Can difficult-to-reuse syringes reduce the spread of HIV among injection drug users? 1998
Is crack cheaper than (powder) cocaine? 1998
Modeling the domestic distribution network for illicit drugs 1998
Are Mandatory Minimum Drug Sentences Cost-Effective? 1997
Enforcement or Treatment? : Modeling the Relative Efficacy of Alternatives for Controlling Cocaine 1997
Examining the Behavioral Assumptions of the National Drug Control Strategy 1997
Mandatory Minimum Drug Sentences: Throwing Away the Key or the Taxpayers' Money? 1997
The Meaning and Utility of Drug Prices 1997
Setting Goals for Drug Policy: Harm Reduction or Use Reduction? 1997
What does mathematical modeling tell us about harm reduction? 1997
Cocaine consumption in the United States : estimating past trends and future scenarios 1996
Describing DAWN's dominion 1996
Can the Military Help Prevent Drug Use Among Youth? 1995
Dealing with the country's drug problem 1995
Domestic Geographic Variation in Illicit Drug Prices 1995
Evaluating the effectiveness of interdiction and source country control 1995
Redefining the Goals of National Drug Policy: Recommendations from a Working Group 1995
To How Many Customers Should a Drug Dealer Sell? 1995
Developing Price Series for Cocaine 1994
Examining the Behaviorial Assumptions of the National Drug Control Strategy 1994
Improving Data and Analysis to Support National Drug Abuse Policy — Main Report 1994
Preventing Drug Use Among Youth Through Community Outreach: The Military's Pilot Programs 1994
Three Strikes and You’re Out: Estimated Benefits and Costs of California’s New Mandatory-Sentencing Law 1994
What is the Average Price of an Illicit Drug? 1994
Improving Data and Analysis to Support National Substance Abuse Policy 1993
ONDCP’s First Four Years as a Policy Agency 1993
Simulation of Adaptive Response: A Model of Drug Interdiction 1993

Jonathan P. Caulkins — Publications

America's Opioid Ecosystem: How Leveraging System Interactions Can Help Curb Addiction, Overdose, and Other Harms 2023

The Ecosystem Approach to Opioid Policy 2023

How Much Illegally Manufactured Fentanyl Could the U.S. Be Consuming? 2022

Rapid Changes in Illegally Manufactured Fentanyl Products and Prices in the United States 2022

Cannabis Legalization and Social Equity: Some Opportunities, Puzzles, and Trade-Offs 2021

Heroin Use Cannot Be Measured Adequately with a General Population Survey 2021

The Dawn of a New Synthetic Opioid Era: The Need for Innovative Interventions 2020

Variation in the Degree of Concentration of Prescription Opioid Utilization Using Different Measures 2020

After the Grand Opening: Assessing Cannabis Supply and Demand in Washington State 2019

The Future of Fentanyl and Other Synthetic Opioids 2019

Supervised Consumption Sites: A Nuanced Assessment of the Causal Evidence 2019

The Synthetic Opioid Surge in the United States: Insights from Mortality and Seizure Data 2019

Triangulating Web & General Population Surveys: Do Results Match Legal Cannabis Market Sales? 2019

Understanding America's Surge in Fentanyl and Other Synthetic Opioids 2019

What America's Users Spend on Illegal Drugs, 2006–2016 2019

Acceptability of Heroin-Assisted Treatment and Supervised Drug Consumption Sites to Address the Opioid Crisis in the United States: Key Informant Perspectives 2018

Assessing the Evidence on Supervised Drug Consumption Sites 2018

Big Data on a Big New Market: Insights from Washington State's Legal Cannabis Market 2018

Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States 2018

Variation in Cannabis Potency and Prices in a Newly Legal Market: Evidence from 30 Million Cannabis Sales in Washington State 2017

Considering Marijuana Legalization Carefully: Insights for Other Jurisdictions from Analysis for Vermont 2016

Marijuana Legalization: What Everyone Needs to Know (Second Edition) 2016

Modeling the Structure and Operation of Drug Supply Chains: The Case of Cocaine and Heroin in Italy and Slovenia 2016

Beyond Prevalence: Importance of Estimating Drug Consumption and Expenditures 2015

Cocaine's Fall and Marijuana's Rise: Questions and Insights Based on New Estimates of Consumption and Expenditures in U. S. Drug Markets 2015

Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions 2015

How Much of the Cocaine Market Are We Missing? Insights from Respondent-Driven Sampling in a Mid-Sized American City 2015

The Marijuana Legalization Debate: Insights for Vermont 2015

Options and Issues Regarding Marijuana Legalization 2015

Are Users' Most Recent Drug Purchases Representative? 2014

Criminal Justice Costs of Prohibiting Marijuana in California 2014

Developing Public Health Regulations for Marijuana: Lessons from Alcohol and Tobacco 2014

How Big Is the U.S. Market for Illegal Drugs? 2014

What America's Users Spend on Illegal Drugs: 2000–2010 2014

Before the Grand Opening: Measuring Washington State's Marijuana Market in the Last Year Before Legalized Commercial Sales 2013

Estimating the Size of the EU Cannabis Market 2013

High Tax States: Options for Gleaning Revenue from Legal Cannabis 2013

Multinational overview of cannabis production regimes 2013

Quasi-legal Cannabis in Colorado and Washington: Local and National Implications 2013

Statistics on Cannabis Users Skew Perceptions of Cannabis Use 2013

The Whole Is Just the Sum of Its Parts: Limited Polydrug Use Among the "Big Three" Expensive Drugs in the United States 2013

Design Considerations for Legalizing Cannabis: Lessons Inspired by Analysis of California's Proposition 19 2012

Epidemiological Model for Examining Marijuana Use Over the Life Course 2012

Scheduling of Newly Emerging Drugs: A Critical Review of Decisions Over 40 Years 2012

The U.S. Drug Policy Landscape: Insights and Opportunities for Improving the View 2012

Addiction Research Centres and the Nurturing of Creativity: RAND's Drug Policy Research Center 2011

Basing Drug Scheduling Decisions on Scientific Ranking of Harmfulness: False Promise from False Premises 2011

Bringing Perspective to Illicit Markets: Estimating the Size of the U.S. Marijuana Market 2011

Budgeting for Immigration Enforcement: A Path to Better Performance 2011

Altered State? Assessing How Marijuana Legalization in California Could Influence Marijuana Consumption and Public Budgets 2010

Cost of Marijuana Prohibition on the California Criminal Justice System 2010

Estimated Cost of Production for Legalized Cannabis 2010

How Might Marijuana Legalization in California Affect Drug Trafficking Revenues and Violence in Mexico? 2010

How Might Marijuana Legalization in California Affect Public Budgets and Marijuana Consumption? 2010

Potential for Legal Marijuana Sales in California to Supply Rest of U.S. 2010

RAND Review: Vol. 34, No. 2, Summer 2010 2010

Reducing Drug Trafficking Revenues and Violence in Mexico: Would Legalizing Marijuana in California Help? 2010

Smuggling and Excise Tax Evasion for Legalized Marijuana: Lessons from Other Excise Taxes 2010

What Economics Can Contribute to the Addiction Sciences 2010

Marijuana Markets: Inferences from Reports by the Household Population 2006

Assessing U.S. Drug Problems and Policy: A Synthesis of the Evidence to Date 2005

How Goes the “War on Drugs”? An Assessment of U.S. Drug Problems and Policy 2005

Models Pertaining to How Drug Policy Should Vary Over the Course of a Drug Epidemic 2005

What We Can--And Cannot--Expect from School-Based Drug Prevention 2004

Crash Courses: Hard Lessons from Educational Interventions 2003

Drug Use and Drug Policy Futures: Insights from a Colloquium 2003

International Drug Prices: Evidence from STRIDE 2003

RAND Review: Vol. 27, No. 1, Spring 2003 2003

Intelligent Giving: Insights and Strategies for Higher Education Donors 2002

Law Enforcement's Role in a Harm Reduction Regime 2002

A "Noble Bet" in Early Care and Education: Lessons from One Community's Experience 2002

A "Noble Bet" in Early Care and Education: Lessons from One Community's Experience: Executive Summary 2002

School-Based Drug Prevention: What Kind of Drug Use Does It Prevent? 2002

What Are the True Benefits of School-Based Drug Prevention Programs? 2002

Analyzing the Costs and Benefits of Early Childhood Interventions 2001

Assessing Costs and Benefits of Early Childhood Intervention Programs: Overview and Applications to the Starting Early, Starting Smart Program: Executive Summary 2001

Assessing Costs and Benefits of Early Childhood Intervention Programs: Overview and Applications to the Starting Early, Starting Smart Program 2001

Drug Prices and Emergency Department Mentions for Cocaine and Heroin 2001

The Evolution of Drug Initiation: From Social Networks to Public Markets 2001